Research programme: hormone biosimilars - Harvest Moon Pharmaceuticals

Drug Profile

Research programme: hormone biosimilars - Harvest Moon Pharmaceuticals

Alternative Names: EPO biosimilar - Harvest Moon; hGH biosimilar - Harvest Moon; recombinant erythropoietin biosimilar - Harvest Moon; somatotropin biosimilar - Harvest Moon

Latest Information Update: 11 Oct 2013

Price : $50

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Growth hormones; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anaemia; Growth disorders; Somatotropin deficiency

Most Recent Events

  • 11 Oct 2013 Hormone biosimilars are available for licensing as of 11 Oct 2013. http://harvestmoonpharma.com/
  • 11 Oct 2013 Preclinical trials in Anaemia in USA (SC)
  • 11 Oct 2013 Preclinical trials in Growth disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top